InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.00%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.28
(
-0.06%
)
Bitcoin
54,292.84
(
-4.72%
)

Replies to post #221228 on Biotech Values

Replies to #221228 on Biotech Values

DewDiligence

10/04/18 11:12 AM

#221235 RE: biocqr #221228

ARWR -13% on JNJ partnership—investors evidently expected more than $250M up-front for ARWR’s lead compound.

DewDiligence

04/24/19 11:32 AM

#224755 RE: biocqr #221228

ARWR earns $25M HBV milestone from JNJ for start of dosing a new phase-1/2 dosing cohort comprised of JNJ-3989 (f/k/a ARO-HBV) and two undisclosed drugs:

https://www.businesswire.com/news/home/20190424005179/en

The ct.gov listing for the trial provides no information on the identities of the undisclosed drugs (https://www.clinicaltrials.gov/ct2/show/NCT03365947 ).